1 / 15

Evidence-Based Medicine Critical Appraisal of Therapy

Evidence-Based Medicine Critical Appraisal of Therapy. Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences Library. ?. Clinical Importance. Validity. Applicability. Strategies for Critical Appraisal of Studies on Therapy. ?. Validity.

priscilla-boyd
Download Presentation

Evidence-Based Medicine Critical Appraisal of Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evidence-Based MedicineCritical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences Library

  2. ? Clinical Importance Validity Applicability Strategies for Critical Appraisal of Studies on Therapy

  3. ? Validity Strategies for Critical Appraisal of Studies on Therapy

  4. Judging validity with just 6 questions! 1. Randomized trial with “concealment”.* 2. Follow-up of patients sufficiently long and complete (> 80% follow-up). 3. Intention-to-treat analysis based on initial assignment. 4. Adequate blinding of treatment when possible. 5. Groups treated equally. 6. Groups similar at the start.

  5. No Randomized Trials or Published Studies Fall Short? • Try repeating your search. • Is the treatment effect so huge in other published studies you can’t ignore it. • If non-randomized trial says a treatment is worthless it probably is. • Consider an “n-of-1” trial. • Consider other treatment options. See textbook for details.

  6. ? Clinical Importance Strategies for Critical Appraisal of Studies on Therapy

  7. Judging clinical importance with just 2 questions! 1. What is the magnitude of the treatment effect? RRR = (Control ER - Experimental ER)/Control ER ARR = Control ER - Experimental ER NNT = 1/ARR (Conversely NNH = 1/ARI) 2. How precise is this estimate of the treatment effect? 95% CI - range of values within which we can be 95% sure that the population value lies.

  8. Calculating NNT/NNH 1. A randomized trial of new drug “Ligatite” reveals that 25% of World Cup skiers who take the drug for one year have ACL tears whereas 50% of World Cup skiers who take the placebo for the year have ACL tears. What is the NNT? NNT = 1/ARR = 1/(0.50-0.25) = 4 2. An advertisement for a new drug designed to prevent pheochromocytoma highlights a relative risk reduction over 5 years of 90%. You read the study supporting the claim and find the study valid. What is the NNT? Unknown without knowing the event rate in the control population. 3. The study of the drug “Ligatite” also notes that 5% of athletes taking the drug develop clinical depression whereas 3% of athletes taking the placebo develop depression. What is the NNH? NNH = 1/ARI = 1/(0.05-0.03) = 50

  9. Examples of NNT http://www.cebm.utoronto.ca/glossary/nnts.htm#table

  10. ? Applicability Strategies for Critical Appraisal of Studies on Therapy

  11. Applicable to Our Patient? 1. Is our patient so different from those in the study that its results cannot apply? 2. Is the treatment feasible in the setting? 3. What are our patient’s potential benefits and harms from the therapy? 4. What are our patient’s values and expectations for both the outcome and the treatment? See textbook for details of LHH (likelihood of being helped vs. harmed)

  12. Estimating Our Patient’s Expected Event Rates (PEER) 1. Assign our patient the overall control event rate from the study. 2. If there is a subgroup of patients in the study with similar characteristics assign the event rate for that subgroup. 3. If a validated clinical predication guide is available use it to assign an event rate. 4. Look for a different paper that describes the prognosis of untreated patients more similar to our patient and use its results to assign an event rate.

  13. Returning to “Ligatite” A randomized trial of new drug “Ligatite” reveals that 25% of World Cup skiers who take the drug for one year have ACL tears whereas 50% of World Cup skiers who take the placebo for the year have ACL tears. Your patient reads about this in Ski Magazine and asks you to write a prescription. In discussing the medication with her you want to provide her with an estimate of the magnitude of risk reduction she would realize. Is her NNT = 4? No: 1. Her risk of an ACL tear is substantially less so you have to re-estimate her expected event rate. 2. She is unlikely to be skiing year round. So: Look to see if there are data estimating the seasonal risk of ACL tear in a population representing your patient and adjust the ARR in the trial to reflect 6 months of treatment.

  14. Clinical Tools for Estimating PEER Available at: http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof%09

  15. Therapy Questions

More Related